Related Experiment Videos
Abstract:
The recognition that certain types of ventricular premature beats, specifically repetitive forms, may be forerunners of more serious tachyarrhythmias has led to the practice of prophylactic therapy with antiarrhythmic drugs to suppress these forms in patients who have underlying cardiac disease. Several antiarrhythmic drugs are available for oral therapy, and many others are undergoing investigation. The usefulness of these agents is often limited by frequent side effects, which include idiosyncratic and unpredictable reactions that are not related to drug level. One such effect is the aggravation of the arrhythmia being treated. Noninvasive drug testing in 245 patients for a total of 1024 single drug tests showed 113 studies (11 per cent) to have been aggravated by the antiarrhythmic drug. At least one drug was proarrhythmic in 78 patients (32 per cent). Aggravation of arrhythmia is a potentially serious drug complication that occurs with all antiarrhythmic agents.
Insights
Certain antiarrhythmic drugs used to treat premature ventricular beats can unexpectedly worsen arrhythmias. This proarrhythmic effect occurred in 11% of tests, highlighting a significant risk with these cardiac medications.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Repetitive ventricular premature beats can precede serious tachyarrhythmias.
- Prophylactic antiarrhythmic drug therapy is used to suppress these beats in cardiac patients.
- Existing antiarrhythmic drugs have limitations due to frequent and unpredictable side effects.
Purpose of the Study:
- To evaluate the incidence of arrhythmia aggravation by antiarrhythmic drugs.
- To identify the proarrhythmic potential of oral antiarrhythmic agents.
Main Methods:
- Noninvasive drug testing was performed.
- 245 patients underwent 1024 single drug tests.
Main Results:
- 11% of drug tests (113/1024) showed arrhythmia aggravation.
- 32% of patients (78/245) experienced proarrhythmia with at least one drug.
- Arrhythmia aggravation is a common complication across all tested antiarrhythmic agents.
Conclusions:
- Antiarrhythmic drugs can paradoxically worsen cardiac arrhythmias.
- Proarrhythmia is a significant and inherent risk associated with antiarrhythmic therapy.
- Careful patient monitoring is crucial during antiarrhythmic drug treatment.